Abstract

The Protocol Review and Monitoring System (PRMS) of the Tisch Cancer Institute (TCI) oversees all cancer related clinical research conducted at the Mount Sinai Health System (MSHS). The major goal of the PRMS is to assure adequate internal oversight of the scientific aspects of cancer-related research by providing a rigorous initial scientific review and performing ongoing monitoring for scientific progress and accrual onto active cancer protocols. Protocol review is comprised of three components: Biostatistics Design Workshop, Disease Focus Groups, and the Protocol Review and Monitoring Committee (PRMC). Only the PRMC has the authority to open protocols that meet the scientific merit and priorities of the TCI and to terminate protocols that do not demonstrate scientific progress.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA196521-06
Application #
10022670
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
2015-08-01
Project End
2025-07-31
Budget Start
2020-08-01
Budget End
2021-07-31
Support Year
6
Fiscal Year
2020
Total Cost
Indirect Cost

  Institution

Name
Icahn School of Medicine at Mount Sinai
Department
Type
DUNS #
078861598
City
New York
State
NY
Country
United States
Zip Code
10029

  Publications

Buckstein, M; Rhome, R; Ru, M et al. (2018) Neoadjuvant chemoradiation radiation dose levels for surgically resectable esophageal cancer: predictors of use and outcomes. Dis Esophagus 31:
Kamath, Geetanjali R; Taioli, Emanuela; N Egorova, Natalia et al. (2018) Liver Cancer Disparities in New York City: A Neighborhood View of Risk and Harm Reduction Factors. Front Oncol 8:220
Chang, Chan-Jung; Kotini, Andriana G; Olszewska, Malgorzata et al. (2018) Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports 10:1610-1624
Kancherla, Venkatesh; Abdullazade, Samir; Matter, Matthias S et al. (2018) Genomic Analysis Revealed New Oncogenic Signatures in TP53-Mutant Hepatocellular Carcinoma. Front Genet 9:2
Kamath, Geetanjali R; Kim, Michelle K; Taioli, Emanuela (2018) Risk of Primary Neuroendocrine Pancreatic Tumor After a First Primary Cancer: A US Population-Based Study. Pancreas :
Ellis, Erin M; Erwin, Deborah O; Jandorf, Lina et al. (2018) Designing a randomized controlled trial to evaluate a community-based narrative intervention for improving colorectal cancer screening for African Americans. Contemp Clin Trials 65:8-18
Sly, Jamilia R; Miller, Sarah J; Li, Yaqi et al. (2018) Low-dose computed tomography lung cancer screening as a teachable moment for smoking cessation among African American smokers: A feasibility study. J Psychosoc Oncol :1-9
Alter, Harvey; Block, Timothy; Brown, Nathaniel et al. (2018) A research agenda for curing chronic hepatitis B virus infection. Hepatology 67:1127-1131
Galsky, Matthew D; Wang, Huan; Hahn, Noah M et al. (2018) Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes. Eur Urol 73:751-759
Tsuchida, Takuma; Lee, Youngmin A; Fujiwara, Naoto et al. (2018) A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. J Hepatol 69:385-395

Showing the most recent 10 out of 143 publications